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Prolactin Induces Tuberoinfundibular Dopaminergic Neurone
Differentiation in Snell Dwarf Mice if Administered Beginning at 3 Days
of Age
C. E. Khodr, D. L. Hurley
1 and C. J. Phelps
Neuroscience Program, Tulane University School of Medicine, New Orleans, LA, USA.
Prolactin secretion is inhibited by dopamine (1), primarily secreted
from tuberoinfundibular dopaminergic (TIDA) neurones. These neuro-
nes are located in the arcuate nucleus (ARC) of the hypothalamus
and project to the external median eminence (ME) where dopamine is
released into the pituitary portal vessels. Prolactin feedback to TIDA
neurones increases tyrosine hydroxylase (TH) activity, which is the
rate-limiting enzyme in dopamine synthesis (2). Besides dynamic
feedback, prolactin also affects the development of TIDA neurones.
The feedback effects of prolactin on TIDA neurones can be
studied in models that lack prolactin. Ames (3) and Snell (4)
dwarf mice lack pituitary prolactin, growth hormone and thyroid-
stimulating hormone due to spontaneous mutation in the gene
encoding transcription factor Prop-1 (df⁄df) or Pit-1 (dw⁄dw),
respectively (5, 6). These mice lack prolactin feedback to TIDA
neurones and exhibit a deﬁcient TIDA neurone population (7–9),
as well as reduced hypothalamic dopamine (10–12). In Ames
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The hypothalamic tuberoinfundibular dopaminergic (TIDA) neurones secrete dopamine, which
inhibits prolactin secretion. TIDA neurone numbers are deﬁcient in Ames (df⁄df) and Snell (dw⁄dw)
dwarf mice, which lack prolactin, growth hormone and thyroid-stimulating hormone. Prolactin
therapy initiated before 21 days maintains normal-sized TIDA neurone numbers in df⁄df mice and,
when initiated as early as 7 days, maintains the maximum TIDA neurone numbers observed in
dw⁄dw development, which are decreased compared to those in normal mice. The present study
investigated the effect of prolactin dose and species on TIDA neurone development. Snell dwarf
and normal mice were treated with saline, 5 lg of ovine prolactin (oPRL), 50 lg of oPRL, or 50 lg
of recombinant mouse prolactin (rmPRL) beginning at 3 days of age. Brains were analysed at
45 days using catecholamine histoﬂuorescence, and immunohistochemistry for tyrosine hydroxy-
lase or bromodeoxyuridine. Normal mice had greater (P £ 0.01) TIDA neurones than dw⁄dw,
regardless of treatment. TIDA neurones in 50 lg oPRL-treated dw⁄dw mice were greater
(P £ 0.05) than those in 5 lg oPRL- and rmPRL-treated dw⁄dw mice, which were greater
(P £ 0.01) than those in saline-treated dw⁄dw mice. Fifty microgram oPRL-treated dw⁄dw mice
also had greater (P < 0.01) TIDA neurone numbers than the maximum numbers observed in
untreated dw⁄dw mice development. Among saline, 5 lg oPRL and 50 lg oPRL treatments, but
not rmPRL, A14 neurone numbers were higher (P £ 0.01) in normal compared to in dw⁄dw mice.
The mechanism of TIDA neurone recruitment was investigated using bromodeoxyuridine (BrdU)
treatment at intervals after 21 days. Mice treated with rmPRL, but not oPRL, had increased BrdU
incorporation in the periventricular area surrounding the third ventricle and median eminence and
in the arcuate nucleus. The data obtained in the present study indicate that oPRL, but not rmPRL,
when given at a high enough dose, induces TIDA neurone differentiation in dw⁄dw mice. This sup-
ports neurotrophic effects of prolactin on TIDA neurones in early postnatal development that
extends beyond maintenance of the cell population.
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From Molecular to Translational Neurobiologydwarf mice, chronic ovine prolactin (oPRL) treatment initiated
prior to 21 days of age has been demonstrated to maintain a
normal-sized TIDA neurone population (13–15). Snell dwarf mice,
however, exhibit an earlier and more severe TIDA neurone deﬁcit
(23% of that in normal) than Ames dwarf mice (48% of that in
normal). Ames dwarf mice establish a normal-sized TIDA neurone
population during development and exhibit a deﬁcient TIDA neu-
rone number by 30 days of age (16). However, Snell dwarf mice
never establish a TIDA neurone population comparable to that in
normal mice (Dw⁄dw) and exhibit a deﬁcient TIDA neurone num-
ber by 14 days of age (9). Daily oPRL treatment of Snell dwarf
mice beginning at 12 or 7 days of age maintains the maximum
TIDA neurone numbers observed throughout Snell dwarf develop-
ment, but does not induce the differentiation of a normal-sized
TIDA neurone population (9). Although long-term, homologous
prolactin treatment of adult Snell dwarf mice induces differentia-
tion of TIDA neurones (17), the documented effects of prolactin
in early postnatal development of Ames and Snell dwarf mice
suggest that prolactin inhibits TIDA cell death or loss of pheno-
type, rather than induces differentiation.
The present study investigated whether the TIDA neurone deﬁcit
in Snell dwarf mice could be prevented with early postnatal pro-
lactin therapy. Because of the early and severe TIDA neurone deﬁ-
cit observed in Snell dwarf mice, along with the effect of
prolactin on TIDA neurones if therapy is initiated at 7 days of
age, prolactin treatment was initiated at 3 days of age in the
present study. The effect of dose and species of prolactin on TIDA
neurones in Snell dwarf mice also was examined. Snell dwarf and
normal mice were treated daily with recombinant mouse prolactin
(rmPRL) or oPRL beginning at 3 days of age. Both species of pro-
lactin were hypothesised to induce TIDA neurone differentiation,
although rmPRL was hypothesised to be more potent in this
effect than oPRL. The mechanism of the hypothesised prolactin-
induced recruitment of new TIDA neurones also was investigated
using bromodeoxyuridine (BrdU) treatment aiming to assess
whether neurogenesis is responsible for increased TIDA neurone
number.
Materials and methods
Animals
Snell dwarf (dw⁄dw) and normal (DW⁄dw) mice were produced from
matings of DW⁄dw females with dw⁄dw males. Dwarf males were trea-
ted with D⁄ L-thyroxine (2 lg, i.p.; Sigma, St Louis, MO, USA) three times
a week beginning at 5 weeks of age, and underwent renal capsule pitui-
tary graft surgery from DW⁄dw donors at 9 weeks of age to induce fer-
tility. Mice undergoing surgery were anaesthetised with isoﬂurane.
Donors, which included DW⁄dw males and females aged 2–12 months,
were anaesthetised with sodium pentobarbital and decapitated for pitui-
tary gland removal. Whole single glands were placed under the kidney
capsule of recipient mice. The breeding colony was maintained under a
12 : 12 h light⁄dark cycle (lights on 06.00 h) and controlled temperature
(22  2  C) with food and water available ad lib. Animal use procedures
were approved by the Tulane University School of Medicine Animal Care
and Use Committee.
Treatments
DW⁄dw and dw⁄dw littermates were treated with saline, 5 lg of oPRL,
50 lg of oPRL or 50 lg of rmPRL (National Hormone and Pituitary Pro-
gram, National Institute of Diabetes and Digestive and Kidney Diseases),
daily, beginning at 3 days of age and continuing until 44 days of age. Lit-
ters treated with saline (0.03 M NaHCO3⁄0.15 M NaCl) beginning at 3 days
of age served as controls. Treatment solutions were administered subcuta-
neously for the ﬁrst 5 days due to solution leakage out of the intraperito-
neal space at this age. After the ﬁrst ﬁve treatment days, treatment
solution was administered into the intraperitoneal space. Each treatment
group contained mice from two or three separate litters. Numbers of mice
for each experimental group were: saline (DW⁄dw, n = 10; dw⁄dw, n = 6),
5 lg of oPRL (DW⁄dw, n = 10; dw⁄dw, n = 11), 50 lg of oPRL (DW⁄dw,
n = 15; dw⁄dw, n = 14) or 50 lg of rmPRL (DW⁄dw, n = 3; dw⁄dw,
n = 3). All mice also were treated with BrdU (50 lg⁄g, i.p.; Sigma) at 21,
31, 39 and 42 days of age and euthanised by perfusion at 45 days of
age.
Tissue preparation and induction of catecholamine
ﬂuorescence
At 45 days of age, mice were weighed and anaesthetised with sodium
pentobarbital (120 mg⁄kg body weight). They were then perfused transcar-
dially with 0.9% NaCl followed by 4% paraformaldehyde–0.5% glutaralde-
hyde (Faglu) ﬁxative (18). After perfusion, brains were removed and
postﬁxed overnight at 4  C, then transferred to 30% sucrose–Faglu solu-
tion to prevent ice crystal formation. Brains were sectioned coronally at
30 lm using a sliding microtome (Reichert; now Leica Microsystems,
Wetzlar, Germany), once saturated with sucrose–Faglu. Brain sections were
divided into six serial sets, each representative of the entire brain, and
post-ﬁxed overnight. Every sixth section (180 lm apart), mounted out of
Faglu, was examined for ﬁxative-induced catecholamine ﬂuorescence using
narrow-band excitation wavelengths (395–415 nm) and a violet barrier ﬁl-
ter (460 nm) on a Nikon E800 microscope (Nikon, Tokyo, Japan) equipped
for ﬂuorescence epi-illumination. Remaining sections were stored in cryo-
protectant antifreeze (19) at )20  C.
Immunohistochemistry for TH or BrdU
Tissue sections taken from cryoprotectant were rinsed in 0.1 M phos-
phate-buffered saline (PBS), pre-treated with 0.1% hydrogen peroxide to
inhibit endogenous peroxidase activity and incubated in 1% aqueous
sodium borohydride to reduce glutaraldehyde-ﬁxed linkages and allow
antibody access. Sections immunostained for BrdU, but not TH, were
incubated in 6 N HCl for 15 min to denature double-stranded DNA. After
further rinsing with PBS, sections immunostained for either BrdU or TH
were incubated in 1.5% normal rabbit serum for 1 h to reduce nonspe-
ciﬁc staining. Sections were then incubated with sheep a-TH
(0.025 lg⁄ml; Pel-Freeze, Rogers, AR, USA) or sheep a-BrdU (0.05 lg⁄ml;
Abcam, Cambridge, MA, USA) for 48 h at room temperature and pro-
cessed further using biotinylated rabbit a-sheep immunoglobulin G
(1 : 200; Vector Laboratories, Burlingame, CA, USA) and avidin–biotin
complex solutions (Vectastain kit; Vector Laboratories). Development with
0.02% diaminobenzedine tetrahydrochloride (DAB) and 0.003% H2O2 in
Tris buffer allowed visualisation of immunoreactivity. 0.5% NiSO4 was
added to the DAB solution for visualisation of BrdU immunoreactivity.
Sections were then mounted, dried and coverslipped using DPX mountant
for microscopy (Fisher Chemical Co., Pittsburgh, PA, USA). Each immuno-
histochemistry run used identical antiserum aliquots and reagents.
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TH-immunoreactive neurones in hypothalamic dopaminergic areas A12
(TIDA), A13 (zona incerta) and A14 (periventricular nucleus), according to
the classiﬁcation of Bjo ¨rklund and Nobin (20), were manually quantiﬁed at
180-lm intervals. Cell counts were not corrected for re-counted or missed
cells because section thickness (30 lm) and interval (180 lm) exceeded
perikaryal diameter (21), but cell counts were corrected for periodicity (· 6,
for every sixth section).
BrdU cell counts
BrdU-immunoreactive cells were manually quantiﬁed at · 40 magniﬁcation
in the subventricular zone (SVZ) of the lateral ventricle (LV), the dentate
gyrus (DG), the periventricular region surrounding the third ventricle (3V)
and ME, and the ARC. BrdU-immunoreactive cells in the entire SVZ were
quantiﬁed beginning at the wall of the LV and extending approximately
25 lm into the surrounding tissue. BrdU-immunoreactive cells in the peri-
ventricular region surrounding the 3V were quantiﬁed beginning at the wall
of the 3V and extending approximately 60 lm into the surrounding tissue,
excluding the ARC. Sample sizes for BrdU cell counts were: saline (DW⁄dw,
n = 5; dw⁄dw, n = 5), 5 lg of oPRL (DW⁄dw, n = 5; dw⁄dw, n = 5), 50 lg
of oPRL (DW⁄dw, n = 5; dw⁄dw, n = 6) or 50 lg of rmPRL (DW⁄dw, n = 3;
dw⁄dw, n = 5). Cell counts were corrected for periodicity (· 6, for every
sixth section).
Imaging for illustrations
A DX1200 colour digital camera on a Nikon E800 microscope was used to cap-
ture images of endogenous catecholamine ﬂuorescence, TH immunostaining
and BrdU immunostaining. Images were composited into multi-photo plates
using Adobe Photoshop 7.0 (Adobe Systems, San Jose, CA, USA).
Statistical analysis
ANOVA (SuperANOVA; Abacus Concepts, Berkeley, CA, USA) and Student
Newman–Keuls post-hoc tests were used to statistically analyse data.
Two-way ANOVA was initially used to identify signiﬁcant effects. If signiﬁcant
effects were observed in the two-way ANOVA, one-way ANOVA was performed
with post-hoc tests. P < 0.05 was considered statistically signiﬁcant.
Results
Body weight
Body weights of DW⁄dw and dw⁄dw treated daily with saline, 5 lg
of oPRL, 50 lg of oPRL or 50 lg of rmPRL beginning at 3 days
of age are shown in Fig. 1. There was an interaction of sex and
genotype on body weight (F1,68 = 4.5, P = 0.0369). Sex affected
body weight in DW⁄dw (F1,36 = 11.5, P = 0.0017), but not in
dw⁄dw; male DW⁄dw (23.8  0.4 g, n = 24) weighed more
(P £ 0.01) than female DW⁄dw (21.5  0.6 g, n = 14). Although
sex affected body weight in DW⁄dw, genders were pooled because
there was a parallel insigniﬁcant effect of treatment on male and
female DW⁄dw. Treatment signiﬁcantly affected body weight in
dw⁄dw (F3,30 = 18.0, P = 0.0001), but not in DW⁄dw. Dwarf mice
treated with 50 lg of oPRL (9.1  0.3 g, n = 14) weighed more
(P £ 0.05) than dw⁄dw treated with 5 lg of oPRL (7.9  0.2 g,
n = 11), which weighed more (P £ 0.05) than dw⁄dw treated with
saline (6.7  0.2 g, n = 6). Linear regression analysis showed a
dose-dependent effect of oPRL treatment (r = 0.9999) on body
weight in dw⁄dw. Dwarfs treated with 5 lg of oPRL weighed more
(P £ 0.01) than dw⁄dw treated with rmPRL (6.3  0.3 g, n = 3),
which had similar weights to dw⁄dw treated with saline. Genotype
had an effect on body weight, regardless of treatment
(F1,70 = 1122.8, P = 0.0001). In all treatment groups, dw⁄dw
(8.1  0.2 g, n = 34) weighed less (P £ 0.01) than DW⁄dw
(22.9  0.4 g, n = 38).
Catecholamine ﬂuorescence
Figure 2 illustrates catecholamine ﬂuorescence in TIDA neurones
and ME of normal (DW⁄dw) and Snell dwarf (dw⁄dw) mice treated
daily with saline, 5 lg of oPRL, 50 lg of oPRL, or 50 lg of rmPRL
beginning at 3 days of age. Catecholamine ﬂuorescence was quali-
tatively evaluated. Among DW⁄dw, TIDA neurone ﬂuorescence in
50 lg oPRL-treated mice was elevated compared to that in
rmPRL-treated mice, which was elevated compared to that in 5 lg
oPRL- or saline-treated mice. ME ﬂuorescence was similar in all
DW⁄dw treatment groups. Dwarf mice treated with 5 or 50 lgo f
oPRL had slightly higher ME ﬂuorescence than dw⁄dw treated with
saline or rmPRL. rmPRL-treated dwarf mice had slightly higher TIDA
ﬂuorescence than saline and 5 lg oPRL-treated dw⁄dw and lower
TIDA ﬂuorescence than 50 lg oPRL-treated dw⁄dw. In saline-, 5 lg
oPRL-, and rmPRL-treated mice, DW⁄dw TIDA perikaryal and ME
ﬂuorescence was increased compared to that in dw⁄dw. Normal
and dwarf mice treated with 50 lg of oPRL had similar TIDA neu-
rone ﬂuorescence, but ME ﬂuorescence in DW⁄dw was elevated
compared to that in dw⁄dw. Dopamine ﬂuorescence in nonhypo-
physiotrophic regions was similar between genotypes and treat-
ments (data not shown).
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Fig. 1. Body weights of Snell dwarf (dw⁄dw; black columns) and normal
(DW⁄dw; grey columns) mice treated with saline, 5 lg of ovine prolactin
(oPRL), 50 lg of oPRL or 50 lg of recombinant mouse prolactin (rmPRL)
beginning at 3 days of age. Data are the mean  SEM. Sample size for each
experimental group: saline (DW⁄dw, n = 10; dw⁄dw, n = 6), 5 lg of oPRL
(DW⁄dw, n = 10; dw⁄dw, n = 11), 50 lg of oPRL (DW⁄dw, n = 15; dw⁄dw,
n = 14) and 50 lg of rmPRL (DW⁄dw, n = 3; dw⁄dw, n = 3). Asterisks indi-
cate differences between dwarf and normal (**P < 0.01). Letters indicate dif-
ferences between treatments (a and b, b and c differ by P < 0.05; a and c
differ by P < 0.01).
560 C. E. Khodr et al.
ª 2009 The Authors. Journal Compilation ª 2009 Blackwell Publishing Ltd, Journal of Neuroendocrinology, 21, 558–567TH immunoreactivity
ARC and ME TH immunoreactivity in DW⁄dw and dw⁄dw treated
daily with saline, 5 lg of oPRL, 50 lg of oPRL or 50 lg of rmPRL,
beginning at 3 days of age, are shown in Fig. 3. TH immunoreactivity
was qualitatively similar in DW⁄dw regardless of treatment. A quali-
tative dose dependent effect of oPRL was seen in dw⁄dw, with sal-
ine-treated dw⁄dw having the least TH immunoreactivity and 50 lg
oPRL-treated dw⁄dw having the most TH immunoreactivity. TH
immunostaining in dw⁄dw treated with rmPRL was similar to that in
dw⁄dw treated with 5 lg of oPRL. All dw⁄dw mice had reduced TH
immunostaining in TIDA neurones and ME compared to DW⁄dw.
Immunostaining for TH in nonhypophysiotrophic regions was qualita-
tively similar between genotypes and treatments (data not shown).
Neurone numbers immunoreactive for TH in areas A12, A13 and
A14 of DW⁄dw and dw⁄dw treated daily with saline, 5 lg of oPRL,
50 lg of oPRL or 50 lg of rmPRL, beginning at 3 days of age, are
shown in Fig. 4. Genders were pooled in saline, 5 lg of oPRL, and
50 lg of oPRL treatment groups because three-way ANOVA indicated
no effect of sex on neurone number in any area examined for TH
immunoreactivity. There was a signiﬁcant effect of treatment on
area A12 neurone number in dw⁄dw (F4,30 = 74.1, P = 0.0001), but
not in DW⁄dw. Dwarfs treated with 50 lg of oPRL (1857  55,
n = 14) had higher TIDA neurone numbers (P £ 0.01) than dw⁄dw
treated with 5 lg of oPRL (1252  40, n = 11), which had higher
(P £ 0.01) TIDA neurone numbers than dw⁄dw treated with saline
(538  37, n = 6). Linear regression analysis showed that oPRL had
a dose-dependent effect (r = 0.9989) on area A12 neurone number
in dw⁄dw. TIDA neurone numbers in dw⁄dw treated with rmPRL
(1514  63, n = 3) were similar to those in dw⁄dw treated with
5 lg of oPRL, but lower (P £ 0.05) than those in dw⁄dw treated
with 50 lg of oPRL. Furthermore, TIDA neurone number in 50 lg
Saline DW/dw
Saline dw/dw
5 µg oPRL DW/dw
5 µg oPRL dw/dw
50 µg oPRL DW/dw
50 µg oPRL dw/dw
rmPRL DW/dw
rmPRL dw/dw
Fig. 2. Endogenous catecholamine ﬂuorescence in tuberoinfundibular dopaminergic cell bodies and median eminence of Snell dwarf (dw⁄dw, lower panels)
and normal (DW⁄dw, upper panels) mice treated daily with saline, 5 lg of ovine prolactin (oPRL), 50 lg of oPRL or 50 lg of recombinant mouse prolactin
(rmPRL) beginning at 3 days of age. Coronal sections; original objective magniﬁcation: · 20. Scale bar = 100 lm.
Saline DW/dw 5 µg oPRL DW/dw 50 µg oPRL DW/dw rmPRL DW/dw
rmPRL dw/dw 50 µg oPRL dw/dw 5 µg oPRL dw/dw Saline dw/dw
Fig. 3. TH immunoreactivity in tuberoinfundibular dopaminergic neurones and median eminence of Snell dwarf (dw⁄dw, lower panels) and normal (DW⁄dw,
upper panels) mice treated daily with saline, 5 lg of ovine prolactin (oPRL), 50 lg of oPRL or 50 lg of recombinant mouse prolactin (rmPRL) beginning at
3 days of age. Coronal sections; original objective magniﬁcation: · 10. Scale bar = 100 lm.
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TIDA neurone numbers observed in untreated dw⁄dw development
(7–21 days; 1295  139, n = 6; horizontal line in Fig. 4). Dwarfs
treated with 5 lg of oPRL or rmPRL had TIDA neurone numbers
that were similar to the highest numbers observed throughout
dw⁄dw development (7–21 days of age, horizontal line in Fig. 4).
Genotype signiﬁcantly affected TIDA neurone number (F1,71 = 80.4,
P = 0.0001), regardless of treatment. In all treatments, DW⁄dw
(2270  53, n = 38) had higher (P £ 0.01) A12 neurone numbers
than dw⁄dw (1398  87, n = 34). A one-way ANOVA combining
treatment and phenotype indicated that A12 neurone numbers in
50 lg of oPRL-treated dw⁄dw were similar to those in saline
(2296  96, n = 10), 5 lg oPRL (2039  89, n = 10) and rmPRL-
treated DW⁄dw (2204  124, n = 3).
Area A13 neurone number was not affected by treatment. Sal-
ine-treated A13 neurone number was affected by genotype
(F1,14 = 6.6, P = 0.0221); saline-treated DW⁄dw had higher
(P £ 0.05) A13 neurone numbers (1539  74, n = 10) than saline-
treated dw⁄dw (1256  72, n = 6). However, a one-way ANOVA that
combined genotype and treatment indicated no differences in A13
neurone numbers between genotypes and treatments. Because the
one-way ANOVA combining treatment and genotype indicated no dif-
ferences in A13 neurone number, A13 neurone number was consid-
ered comparable between groups. Area A14 neurone number was
not affected by treatment but was signiﬁcantly affected by geno-
type (F1,71 = 96.1, P = 0.0001). A14 neurone numbers were higher
(P £ 0.01) in DW⁄dw (4946  138, n = 35) than in dw⁄dw
(3198  120, n = 31) in saline, 5 lg of oPRL and 50 lg of oPRL
treatments, but not in the rmPRL treatment. One-way ANOVA combin-
ing genotype and treatment (F8,64 = 13.0, P = 0.0001) indicated that
A14 neurone numbers in rmPRL-treated dw⁄dw (3720  134,
n = 3) were similar to those in 50 lg oPRL-treated DW⁄dw
(4611  249, n = 15), but lower (P £ 0.05) than those in saline-
(5147  201, n = 10) and 5 lg oPRL-treated DW⁄dw (5249  162,
n = 10).
BrdU immunoreactivity
Figure 5(A) shows representative illustrations of BrdU immunoreac-
tivity in the periventricular region surrounding the 3V of DW⁄dw
and dw⁄dw treated daily with saline, 5 lg of oPRL, 50 lg of oPRL
(grouped in ﬁgure) or 50 lg of rmPRL beginning at 3 days of age.
Within genotype, immunoreactivity for BrdU was similar between
saline, 5 lg of oPRL and 50 lg of oPRL treatments (not shown) in
the periventricular region surrounding the 3V. However, 3V BrdU
immunostaining in rmPRL-treated mice was qualitatively greater
than that in all other treatments. BrdU incorporation was greater in
DW⁄dw than in dw⁄dw in all treatments.
BrdU immunoreactivity in the ARC of DW⁄dw and dw⁄dw trea-
ted daily with saline, 5 lg of oPRL (grouped in ﬁgure), 50 lgo f
oPRL or 50 lg of rmPRL beginning at 3 days of age, is shown in
Fig. 5(B). Within genotype, mice treated with rmPRL exhibited
greater BrdU incorporation than those treated with saline, 5 lgo f
oPRL, or 50 lg of oPRL, which had qualitatively similar BrdU
immunoreactivity. In mice treated with 50 lg of oPRL or rmPRL,
DW⁄dw had greater BrdU immunoreactivity than dw⁄dw. Dentate
gyrus and SVZ BrdU immunoreactivity was qualitatively similar
between treatments and genotypes (not shown).
**
a
b
c
b
*
** ** **
**
**
**
Saline
Saline
5 µg oPRL
5 µg oPRL
5 µg oPRL 50 µg oPRL rmPRL
50 µg oPRL rmPRL
50 µg oPRL rmPRL
Treatment
Treatment
DW/dw dw/dw
0
1000
2000
3000
4000
5000
6000
7000
A14
T
H
+
 
n
e
u
r
o
n
e
 
n
u
m
b
e
r
T
H
+
 
n
e
u
r
o
n
e
 
n
u
m
b
e
r
T
H
+
 
n
e
u
r
o
n
e
 
n
u
m
b
e
r
0
0
1000
1000
2000
2000
3000
dw/dw DW/dw
Treatment
Saline
dw/dw DW/dw
A12
A13
Fig. 4. Tyrosine hydroxylase-immunoreactive neurone numbers in areas A12
(top), A13 (middle), and A14 (bottom) of Snell dwarf (dw⁄dw, black bars) and
normal (DW⁄dw, grey bars) mice treated daily with saline, 5 lg of ovine pro-
lactin (oPRL), 50 lg of oPRL or 50 lg of recombinant mouse prolactin (rmPRL)
beginning at 3 days of age. Data are the mean  SEM. Asterisks represent dif-
ferences between dwarf and normal (*P < 0.05, **P < 0.01). Letters represent
differences between treatments (a and b, a and c differ by P < 0.01; b and c
differ by P < 0.05). The horizontal line in the top graph represents the maxi-
mum number of tuberoinfundibular dopaminergic neurones observed
throughout untreated Snell dwarf development (7–21 days postnatally) as
reported previously (9).
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of the LV, the DG, the periventricular region surrounding the 3V
and ME, and the ARC of DW⁄dw and dw⁄dw treated daily with
saline, 5 lg of oPRL, 50 lg of oPRL or 50 lg of rmPRL beginning
at 3 days of age. Three-way ANOVA indicated no effect of sex on
any area examined for BrdU immunoreactivity in mice treated
with saline, 5 lg of oPRL, or 50 lg of oPRL, so genders were
pooled.
DW/dw
dw/dw
DW/dw
dw/dw
50 µg oPRL DW/dw
50 µg oPRL dw/dw
rmPRL DW/dw
rmPRL dw/dw
rmPRL DW/dw
rmPRL dw/dw
(A)
(B)
Fig. 5. (A) Bromodeoxyuridine (BrdU) immunoreactivity in the periventricular region surrounding the third ventricle of Snell dwarf (dw⁄dw, lower panels) and
normal (DW⁄dw, upper panels) mice treated with saline, 5 lg of ovine prolactin (oPRL), 50 lg of oPRL (grouped in left panels) or 50 lg of recombinant
mouse prolactin (rmPRL) (right panels) beginning at 3 days of age. Coronal sections; original objective magniﬁcation: · 40. Scale bar = 50 lm. (B) BrdU
immunoreactivity in the median eminence and arcuate nucleus of Snell dwarf (dw⁄dw, lower panels) and normal (DW⁄dw, upper panels) mice treated with
saline, 5 lg of oPRL (grouped in left panels), 50 lg of oPRL (middle panels) or 50 lg of rmPRL (right panels) beginning at 3 days of age. Coronal sections;
original objective magniﬁcation: · 40 . Scale bar = 50 lm.
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the LV were not affected by treatments or genotypes. In the peri-
ventricular region surrounding the 3V and ME, an effect of treat-
ment was observed (F3,33 = 15.1, P = 0.0001) in DW⁄dw and
dw⁄dw. Mice treated with rmPRL had higher (P £ 0.01) 3V peri-
ventricular and ME BrdU-immunoreactive cell numbers
(728  104, n = 6) than mice treated with saline (250  65,
n = 10), 5 lg of oPRL (239  52, n = 10) or 50 lg of oPRL
(147  30, n = 11). Genotype also affected BrdU incorporation in
the periventricular region surrounding the 3V and ME
(F1,35 = 12.9, P = 0.0010) regardless of treatment; BrdU-immuno-
reactive cell numbers were higher (P £ 0.01) in DW⁄dw
(431  65, n = 18) than in dw⁄dw (164  39, n = 19) in all
treatments. A one-way ANOVA combining genotype and treatment
(F7,29 = 30, P = 0.0001) indicated that rmPRL-treated dw⁄dw had
similar 3V and ME BrdU-immunoreactive cell numbers (516  81,
n = 3) to DW⁄dw treated with saline (404  80, n = 5) and 5 lg
of oPRL (366  59, n = 5), and higher (P £ 0.01) BrdU-immuno-
reactive cell numbers than DW⁄dw treated with 50 lg of oPRL
(219  48, n = 5). This one-way ANOVA also indicated that saline
(96  23, n = 5), 5 lg oPRL (112  16, n = 5) and 50 lg oPRL-
treated dw⁄dw (87  15, n = 6) had similar BrdU-immunopositive
cell numbers to DW⁄dw treated with 50 lg of oPRL, and lower
cell numbers than DW⁄dw treated with rmPRL (940  50, n = 3),
saline or 5 lg of oPRL.
In the ARC, an effect of treatment was observed (F3,33 = 17.4,
P = 0.0001) on BrdU incorporation regardless of genotype. In both
DW⁄dw and dw⁄dw, rmPRL-treated mice had higher (P £ 0.01) BrdU
immunoreactive cell numbers (189  40, n = 6) than saline-
(39  11, n = 10), 5 lg oPRL- (41  7, n = 10) or 50 lg oPRL-
treated mice (35  10, n = 11). An effect of genotype also was
observed (F1,35 = 6.911, P = 0.0126) on ARC BrdU immunoreactivity;
50 lg oPRL-treated DW⁄dw had higher (P £ 0.01) BrdU-immunore-
active cell numbers (64  12, n = 5) than 50 lg oPRL-treated
dw⁄dw (11  5, n = 6), and rmPRL-treated DW⁄dw had higher
(P £ 0.05) BrdU-immunoreactive cell numbers (270  36, n = 3)
than rmPRL-treated dw⁄dw (108  11, n = 3). A one-way ANOVA
combining genotype and treatment (F7,29 = 32.1, P = 0.0001)
indicated that rmPRL-treated dw⁄dw had higher (P £ 0.05) BrdU-
immunoreactive cell numbers than saline- (58  18, n = 5), 5 lg
oPRL- (48  11, n = 5), and 50 lg oPRL-treated DW⁄dw.
Discussion
PRL feedback regulates the TIDA neurone population by inducing
the expression of TH (2) and increasing dopamine synthesis and
release (1). However, the effects of prolactin on TIDA neurones
extend beyond this dynamic regulation. Studies from this laboratory
have shown that prolactin can act as a neurotrophhic factor on the
TIDA neurone population (22). Treatment of Ames (13, 14) or Snell
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Fig. 6. Bromodeoxyuridine (BrdU)-immunoreactive cell numbers in the SVZ of the lateral ventricle, the dentate gyrus, the periventricular region surrounding the
third ventricle and the median eminence, and the arcuate nucleus of Snell dwarf (dw⁄dw, black bars) and normal (DW⁄dw, grey bars) mice treated with saline,
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maintains the maximum TIDA neurone numbers observed through-
out untreated dwarf development. This is a normal-sized neurone
population in Ames dwarf mice because Ames dwarf mice establish
a normal-sized TIDA neurone population by 21 days of age, after
which cell numbers decline to 48% of that in normal animals (8).
However, this is a deﬁcient neurone population in Snell dwarf mice
because Snell dwarf mice never establish a normal-sized TIDA neu-
rone number and exhibit a deﬁcit of 23% of that in normal animals
(9). Thus, previous studies investigating the early postnatal effect of
prolactin on TIDA neurones in Ames and Snell dwarf mice suggest
that prolactin only maintains the survival of existing TIDA
neurones (23).
The present study was undertaken to investigate whether the
development of a normal-sized TIDA neurone population could be
induced in response to prolactin in Snell dwarf mice. Because of
the early and severe TIDA neurone deﬁcit observed in Snell dwarf
mice (9), prolactin treatment was initiated at 3 days of age. The
effect of dose and species of prolactin was investigated. As in pre-
vious studies, the present results show that prolactin acts as a
neurotrophic factor on TIDA neurones in Snell dwarf mice. Unlike in
Ames dwarf mice, however, prolactin was shown to induce differ-
entiation of TIDA neurones, rather than solely promote survival of
the maximum numbers seen in development. The high dose (50 lg)
of oPRL induced differentiation of a near-normal TIDA neurone
population in Snell dwarf mice, which never exhibit TIDA neurone
numbers of this quantity during development. The low (5 lg) oPRL
dose only maintained the maximum TIDA neurone numbers seen in
Snell dwarf development (7–21 days; Fig. 4).
The effect of rmPRL on TIDA neurone differentiation was
hypothesised to be more potent than the observed heterologous
prolactin effects because murine and ovine prolactin are only
56% homologous (24). It was therefore postulated that oPRL
would have a lower total active fraction in mouse tissues than
homologous prolactin. However, the present study showed that
the effect of 50 lg of rmPRL on TIDA neurone differentiation was
as potent as that of the low (5 lg) oPRL dose; therefore, rmPRL
did not induce TIDA neurone differentiation. It is possible that
rmPRL has an inverse effect on TIDA neurone number; thus, a
lower dose of homologous prolactin may have a greater effect on
TIDA neurone differentiation. Alternatively, oPRL may have proper-
ties that homologous prolactin lacks. The current data indicate a
somatogenic effect of oPRL that is not observed with homologous
prolactin. Dwarf mice treated with oPRL gained weight in a direct
dose-dependent manner, but dwarf mice treated with homologous
prolactin had similar weights to those treated with saline (Fig. 1).
This oPRL-induced weight gain does not deﬁnitively indicate
somatogenic characteristics of oPRL because the weight gain
may be attributed to adipose gain, a known effect of prolactin,
rather than long bone growth. However, oPRL has been shown to
induce liver insulin-like growth factor-1 gene expression in hypo-
physectomised rats (25), which supports somatogenic characteris-
tics of oPRL. Other possibilities for the observed differential
effects of oPRL and rmPRL on TIDA neurones may include differ-
ences in clearance or differences in transport into the brain. A
comparison of plasma prolactin levels could not be assessed
because the majority of plasma samples were lost in the after-
math of Hurricane Katrina.
The present data clearly indicate that prolactin acts as a neuro-
trophic factor on TIDA neurones. Both heterologous and homolo-
gous prolactin induced survival of the greatest TIDA neurone
numbers observed in untreated Snell dwarf development. This effect
suggests that prolactin inhibits TIDA cell death or phenotype
change, resulting in a less severe TIDA deﬁcit. Although the high
dose of heterologous prolactin was able to induce differentiation of
TIDA neurone numbers greater than those ever seen in Snell dwarf
development, the TIDA deﬁcit was not prevented.
Differentiation of a TIDA neurone population that is larger than
that ever seen in untreated dwarf development in response to a
high enough dose of heterologous prolactin was demonstrated in
the present study. The observed new TIDA neurones could possibly
be recruited through two mechanisms, including neurogenesis
and⁄or differentiation of pre-existing neurones. Although hypotha-
lamic neurogenesis is only thought to occur prenatally, there is
in vitro evidence indicating the postnatal existence of quiescent
hypothalamic progenitor cells. These cells, as well as hippocampal
progenitors, have been shown to differentiate into multiple
neuroendocrine phenotypes in vitro (26). These data indicate that
hypothalamic neurogenesis could possibly occur postnatally if the
quiescent progenitor cells are appropriately stimulated, or if
hippocampal progenitor cells differentiate and migrate to the
hypothalamus. Indeed, BrdU-immunoreactive neurones have been
detected in the hypothalamus in response to brain-derived
neurotrophic factor (27) and ciliary neurotrophic factor (28).
In the present study, the neurogenic effects of prolactin were
investigated as a mechanism for the increased TIDA neurone num-
bers. Shingo et al. (29) have previously demonstrated neurogenic
effects of prolactin in the SVZ of the LV in both male and female
adult mice, resulting in new olfactory interneurones. The results
obtained in the present study indicated treatment and genotype
effects on BrdU incorporation in the periventricular region sur-
rounding the 3V and median eminence, and in the ARC, but not in
the SVZ of the LV or in the DG.
Although the present study indicated no effect of treatment or
genotype on BrdU incorporation in the SVZ of the LV, there was an
insigniﬁcant trend of decreased SVZ BrdU incorporation in response
to increasing oPRL levels in dwarf mice. An inverse insigniﬁcant
trend of oPRL dose and SVZ BrdU immunoreactive cell numbers
observed in the present study conﬂicts with the study by Shingo
et al. (29). However, Shingo et al. (29) demonstrated that rmPRL,
not oPRL, induced SVZ neurogenesis in normal mice. Although not
signiﬁcant, treatment of normal mice with rmPRL, but not oPRL,
induced an increased trend of BrdU incorporation in the SVZ of the
LV, which is in accordance with the results obtained by Shingo
et al. (29). The lack of an observed effect of prolactin treatment in
normal mice may be due to differences in treatment in the present
study compared with that of Shingo et al. (29). Shingo et al. (29)
demonstrated that treatment of normal mice with rmPRL for 6 days
induces SVZ BrdU incorporation and that these cells further migrate
to the olfactory bulb. The treatments in the present study lasted for
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bulb. It is possible that the initial short-term effect of prolactin is
induction of SVZ cell proliferation, after which the new cells
migrate to the olfactory lobe.
Genotype differences were consistent between treatments in the
periventricular region surrounding the 3V and ME; dwarfs experi-
enced less BrdU incorporation compared to normal mice. In the
ARC, there were no genotype differences in saline and 5 lgo f
oPRL-treated mice, but dwarfs treated with 50 lg of oPRL or
rmPRL had lower BrdU incorporation. In both dwarfs and normals,
rmPRL, but not oPRL, induced increased BrdU incorporation in the
periventricular region surrounding the 3V and ME and in the ARC
(Fig. 6).
These results suggest that rmPRL, but not oPRL, induces cell
proliferation in the periventricular region surrounding the 3V and
ME, and the ARC in both dwarf and normal mice. It is unlikely
that the increased ARC cell proliferation contributes to the
observed increase in TIDA neurone number because mice treated
with rmPRL did not exhibit higher TIDA neurone numbers than
those seen in untreated dwarf development (Fig. 4). However, mice
treated with 50 lg of oPRL exhibited greater TIDA neurone num-
bers than those seen in untreated dwarf development, but did not
experience increased BrdU incorporation in any area. Because BrdU
treatment was not initiated until 21 days of age, the mechanism
of TIDA neurone recruitment through neurogenesis cannot be
excluded. It is possible that new neurones are recruited for differ-
entiation to the TIDA phenotype prior to 21 days of age. Alterna-
tively, the increased TIDA neurone population could result from an
induced phenotype change in neighbouring ARC neurones. Because
the ARC contains a heterogeneous neurone population, a wide
variety of neurone types might comprise the target of this pheno-
type change.
There is evidence that dopamine secreted by the A14 neurone
population participates in regulation of prolactin secretion (30).
Previous studies also have indicated an effect of prolactin on
A14 neurone activity (31). In the present study, a deﬁcient A14
neurone number was observed in Snell dwarf mice, conﬁrming
previous reports from this laboratory (17). This observed A14
neurone deﬁcit suggests a possible neurotrophic role of prolactin
on this neurone population. The present study indicated that the
A14 neurone deﬁcit was not affected by heterologous prolactin.
Although homologous prolactin treatment of Snell dwarf mice was
shown to statistically induce near-normal A14 neurone numbers
(comparable to those in normal mice treated with 50 lg of oPRL
or rmPRL), A14 neurone number was not different between
dwarfs. Because of the small number of mice treated with homol-
ogous prolactin (DW⁄dw, n = 3; dw⁄dw, n = 3), as well as the
A14 cell number variation in the rmPRL-treated normal mice, the
observed effects of homologous prolactin on A14 cell numbers in
dwarfs may not be conclusive. However, in our previous studies,
we did not observe induction of A14 neurone differentiation in
response to long-term, homologous prolactin (17). The present
data further support a neurotrophic role for prolactin on A14
neurones and suggest involvement of prolactin and⁄or other
factors (such as growth hormone and⁄or thyroid-stimulating
hormone), possibly in conjunction with prolactin, in A14 neurone
development.
In summary, the present study has demonstrated the promotion
of a near normal-sized TIDA neurone population in response to a
sufﬁciently high dose of heterologous prolactin, suggesting that
prolactin induces differentiation and⁄or proliferation of TIDA neuro-
nes. Because treatment did not affect BrdU-immunoreactive cell
numbers, the demonstrated prolactin-induced TIDA neurone recruit-
ment cannot be attributed to prolactin-induced neurogenesis. Neu-
rogenesis as a mechanism responsible for the increased TIDA
neurone numbers, however, cannot be excluded because BrdU
treatment was not administered for the full course of prolactin
therapy. A dose-dependent effect of heterologous prolactin on TIDA
neurone numbers also was demonstrated. Both homologous prolac-
tin and the low dose of heterologous prolactin only maintained
the greatest TIDA neurone numbers observed in Snell dwarf
development, but did not induce TIDA neurone differentiation. The
results obtained in the present study also conﬁrm previous results
that demonstrate a possible neurotrophic effect of prolactin on A14
neurones.
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